Fig. 1From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicityKaplan-Meier analysis of overall survival (OS, a) and intracranial progression-free survival (PFS, b) for patients receiving concurrent SRS and ipilimumab (blue line) or nivolumab (red line). OS and intracranial PFS were significantly better in SRS and nivolumab groupBack to article page